Trasylol

The attorneys at Sanders Phillips Grossman are ready to help with injuries sustained by a defective product.

Sanders Phillips Grossman, LLC is a joint venture firm of Phillips Law Firm and Sanders Viener Grossman merging the best of the West Coast and East Coast’s top Mass Tort Firms to join forces against America’s greediest drug and medical device companies.

Trasylol Recalled November 5th, 2007

The U.S. Food and Drug Administration (FDA) today announced that, at the agency’s request, Bayer Pharmaceuticals Corp. has agreed to a marketing suspension of Trasylol, a drug used to control bleeding during heart surgery, pending detailed review of preliminary results from a Canadian study that suggested an increased risk for death.

FDA requested the suspension in the interest of patient safety based on the serious nature of the outcomes suggested in the preliminary data. FDA has not yet received full study data but expects to act quickly with Bayer, the study’s researchers at the Ottawa Health Research Institute, and other regulatory agencies to undertake a thorough analysis of data to better understand the risks and benefits of Trasylol.

There are not many treatment options for patients at risk for excessive bleeding during cardiac surgery. Thus, FDA is working with Bayer to phase Trasylol out of the marketplace in a way that does not cause shortages of other drugs used for this purpose.

Until FDA can review the data from the terminated study it is not possible to determine and identify a population of patients undergoing cardiac surgery for which the benefits of Trasylol outweigh the risks. Understanding that individual doctors may identify specific cases where the benefit outweighs the risk, FDA is committed to exploring ways for those doctors to have continued, limited access to Trasylol.

Two weeks ago, FDA was notified that researchers with the Ottawa Health Institute stopped a study on Trasylol because the drug appeared to increase the risk for death compared to two other antifibrinolytic drugs used in the study. Antifibrinolytic drugs help slow the breakdown of blood clots and subsequent excessive bleeding. The preliminary data from this terminated study also suggested that fewer patients receiving the drug experienced serious bleeding events.

On Oct. 26, the FDA issued an Early Communication about an Ongoing Safety Review of Trasylol in response to the Canadian study’s termination. In 2006, the FDA revised the labeling for Trasylol to strengthen its safety warning and limit its approved usage to patients at an increased risk for blood loss and blood transfusion during coronary bypass graft surgery.

 

– source information: fda.gov


Trasylol Recall Latest Update:

Trasylol Pulled From Worldwide Market

FDA says clotting drug poses increased death risk, while company says drug still has benefits.

By: Steven Reinberg | usnews.com

Tags: Trasylol Recall

November 5 , 2007

MONDAY, Nov. 5 (Health Day News) — Bayer AG suspended worldwide sales of Trasylol, a clotting drug-using during heart surgery to prevent bleeding, on Monday following a request from the U.S. Food and Drug Administration to remove the drug from the American market for safety reasons.

Contact Sanders Phillips Grossman for a Free Case Review

Sanders Phillips Grossman is accepting cases for those injured by this product nationally. If you or someone you love has suffered a major complication due to the use of this product, it is important to know that you are not alone. Fill out the free case review, and we will contact you to discuss your claim. Sanders Phillips Grossman has experienced lawyers ready to help you with your questions to get you the compensation you deserve. We have a no-fee promise. If we do not win, you do not owe an attorney fee.